Physician profile
Sarah Beth Stringfield
NPI 1972849743
$18,933.72
in general payments reported to CMS, 2019-2025
36 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 82% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.55 · 2020: $546 · 2021: $7,238 · 2022: $5,387 · 2023: $1,690 · 2024: $1,909 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,711 · Travel and Lodging: $991 · Consulting Fee: $35.00 · Education: $14.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,711.00 |
| Travel and Lodging | $990.97 |
| Consulting Fee | $35.00 |
| Education | $14.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $8,124.54 | 2021-2025 | Ligasure, Interstim, Signia |
| Intuitive Surgical, INC. | $3,558.40 | 2021-2025 | |
| Abbvie INC. | $2,368.48 | 2020-2025 | Rinvoq, Skyrizi, Natrelle Saline-Filled Breast Implants |
| Takeda Pharmaceuticals U.S.A., INC. | $1,965.99 | 2020-2025 | Entyvio, Gattex |
| Merck Sharp & Dohme LLC | $461.29 | 2019-2024 | Dificid, Zerbaxa |
| Organon LLC | $412.83 | 2021-2025 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $202.07 | 2024-2025 | Vowst |
| Janssen Biotech, INC. | $172.67 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.31 | 2020-2022 | |
| Thd America, INC. | $164.32 | 2020-2022 | |
| Axonics, INC. | $138.64 | 2021-2024 | Axonics |
| Lilly USA, LLC | $132.64 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $132.49 | 2020 | |
| Tela Bio, INC. | $121.00 | 2022-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Braintree Laboratories, INC. | $106.91 | 2020-2025 | Suflave, Sutab |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $102.72 | 2021 | |
| Baudax Bio INC. | $67.98 | 2021 | |
| Ferring Pharmaceuticals INC. | $54.43 | 2021 | |
| Activ Surgical, INC. | $53.60 | 2022 | |
| Ethicon US, LLC | $44.71 | 2021-2023 | Echelon Circular, Echelon Endopath, Echelon Flex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.20 | 2024 | |
| Allergan, INC. | $43.52 | 2021 | |
| Medtronic USA, INC. | $38.75 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $37.15 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $28.18 | 2023 | |
| Madrigal Pharmaceuticals | $27.36 | 2024 | Resmetirom |
| Intercept Pharmaceuticals, INC. | $21.37 | 2022 | |
| Kerecis Limited | $20.18 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Integra Lifesciences Corporation | $18.04 | 2021 | |
| Kci USA, INC. | $17.25 | 2021 | |
| W. L. Gore & Associates, INC. | $16.41 | 2023 | Gore Synecor Biomaterial |
| Innovation Technologies INC | $15.22 | 2021 | |
| Acacia Pharma INC | $15.01 | 2021 | |
| Convatec INC. | $12.00 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $11.62 | 2021 | |
| Endo Pharmaceuticals INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Stringfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.